Opthea Strengthens Medical Advisory Board with International Retina Experts

Opthea Expands Medical Advisory Board

Opthea Limited, a clinical-stage biopharmaceutical company focused on developing novel therapies for retinal diseases, has announced a significant expansion of its Medical Advisory Board (MAB). The company has welcomed five internationally recognized retina specialists to join its existing panel of experts 1

1

New Additions to the Board

The newly appointed members of Opthea's Medical Advisory Board include:

1. Dr. Arshad M. Khanani, MD, MA, FASRS
2. Dr. Rishi P. Singh, MD
3. Dr. Charles C. Wykoff, MD, PhD
4. Dr. Jean-François Korobelnik, MD
5. Dr. Tien Y. Wong, MD, PhD

These distinguished professionals bring a wealth of experience and expertise in ophthalmology, particularly in the field of retinal diseases 2

2

Expertise and Contributions

The new board members are renowned for their contributions to retinal research and clinical practice. They have been involved in numerous clinical trials and have published extensively in peer-reviewed journals. Their expertise spans various areas, including age-related macular degeneration (AMD), diabetic retinopathy, and other retinal vascular diseases 1

1

Role of the Medical Advisory Board

Opthea's Medical Advisory Board plays a crucial role in providing strategic guidance and clinical insights to support the company's development programs. The board's expertise will be particularly valuable as Opthea advances its lead asset, OPT-302, a novel VEGF-C/D 'trap' inhibitor 2

2

OPT-302 Development

OPT-302 is currently being evaluated in two pivotal Phase 3 clinical trials for wet AMD. These trials, known as ShORe and COAST, are investigating OPT-302 in combination with standard-of-care anti-VEGF-A therapies. The expansion of the Medical Advisory Board comes at a critical time as Opthea prepares for the potential commercialization of OPT-302 1

1

Related Stories

Breakthrough Oncology Research Fuels Multibillion-Dollar Opportunities in Cancer Therapies

CytoSorbents to Present at Inaugural AAPI Critical Care Medicine Summit

Tevogen Bio Advocates for Long COVID Patients in Congressional Meetings

AI and Healthcare: Roche, Avant Technologies, and Ainnova Partner to Combat Diabetic Retinopathy

Management's Perspective

Dr. Megan Baldwin, CEO and Managing Director of Opthea, expressed enthusiasm about the new appointments. She emphasized the importance of having access to world-class expertise in retinal diseases as the company progresses towards potential regulatory submissions and commercialization of OPT-302 2

2

Impact on Opthea's Future

The addition of these esteemed retina specialists to Opthea's Medical Advisory Board is expected to strengthen the company's position in the ophthalmology and retinal disease space. Their collective experience and insights will be invaluable in guiding Opthea's clinical development strategies and potential future commercial activities 1

1

2